15 January 2018
They will perform a randomized controlled trial of cerebellar transcranial direct current stimulation (tDCS) in patients with SCA3, the most common cause of dominantly inherited cerebellar ataxia. Similar to most of the genetic ataxias, SCA3 is currently untreatable and the investigators will test whether tDCS can provide functionally relevant, symptomatic benefit.

Bart van de Warrenburg
The Hersenstichting has awared a grant for transcranial neuromodulation in ataxia.
They will perform a randomized controlled trial of cerebellar transcranial direct current stimulation (tDCS) in patients with SCA3, the most common cause of dominantly inherited cerebellar ataxia. Similar to most of the genetic ataxias, SCA3 is currently untreatable and the investigators will test whether tDCS can provide functionally relevant, symptomatic benefit.
Bart van de Warrenburg
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items

Grants for science communication at Radboudumc
22 April 2021 Scientists at the Radboudumc have received two KNAW grants, each worth 10,000 euros, for science communication. With the new fund, KNAW underlines importance of making science accessible. read more
UMD Catalist grant for Mohammad Alsady and Federica Conte
24 June 2020They received this award to explore the potential of hiPS-derived skeletal muscle cells as model to investigate muscular pathophysiologic mechanisms in phosphoglucomutase I deficiency.
read more
Bas Bloem elected as new member of the KNAW
30 April 2020 Bas Bloem is an expert in Parkinson's disease. He is also a healthcare innovator, focused on the integration of scientific research and its clinical applications. We congratulate Bas with this election. read more
Towards molecular therapies for Myotonic Dystrophy
1 October 2019ReCognitION, a new 1.3 M€ European project under the leadership of Peter-Bram ‘t Hoen, Baziel van Engelen and Jeffrey Glennon, was kicked-off in Gent.
read more
Useful new test for Parkinson's disease
28 March 2019 Diagnosing Parkinson's is not easy. In particular in the early stages, it can be difficult to distinguish Parkinson's from a group of other disorders that at first sight look identical. read more